CLINICAL_TRIALS
trial_result
· 2021-08-03
Clinical Trial Update: Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria [Phase 4]
Summary
Phase 4 trial update for Acthar in treatment-resistant or treatment-intolerant proteinuria due to idiopathic focal segmental glomerulosclerosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mallinckrodt ARD LLC | Conditions: Idiopathic Focal Segmental Glomerulosclerosis | Phase 4 | Status: COMPLETED | Results posted: 2021-08-03